The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 3 , Pages 667-676, September 2010

Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction

Winner of the C. Walton Lillehei Resident Forum at the 89th Annual Meeting of the American Association for Thoracic Surgery, May 10, 2009, Boston, Mass.

Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa

Received 5 May 2009; received in revised form 3 December 2009; accepted 28 December 2009. published online 05 April 2010.

Objective

Microvascular malperfusion after myocardial infarction leads to infarct expansion, adverse remodeling, and functional impairment. Native reparative mechanisms exist but are inadequate to vascularize ischemic myocardium. We hypothesized that a 3-dimensional human fibroblast culture (3DFC) functions as a sustained source of angiogenic cytokines, thereby augmenting native angiogenesis and limiting adverse effects of myocardial ischemia.

Methods

Lewis rats underwent ligation of the left anterior descending coronary artery to induce heart failure; experimental animals received a 3DFC scaffold to the ischemic region. Border-zone tissue was analyzed for the presence of human fibroblast surface protein, vascular endothelial growth factor, and hepatocyte growth factor. Cardiac function was assessed with echocardiography and pressure–volume conductance. Hearts underwent immunohistochemical analysis of angiogenesis by co-localization of platelet endothelial cell adhesion molecule and alpha smooth muscle actin and by digital analysis of ventricular geometry. Microvascular angiography was performed with fluorescein-labeled lectin to assess perfusion.

Results

Immunoblotting confirmed the presence of human fibroblast surface protein in rats receiving 3DFC, indicating survival of transplanted cells. Increased expression of vascular endothelial growth factor and hepatocyte growth factor in experimental rats confirmed elution by the 3DFC. Microvasculature expressing platelet endothelial cell adhesion molecule/alpha smooth muscle actin was increased in infarct and border-zone regions of rats receiving 3DFC. Microvascular perfusion was also improved in infarct and border-zone regions in these rats. Rats receiving 3DFC had increased wall thickness, smaller infarct area, and smaller infarct fraction. Echocardiography and pressure–volume measurements showed that cardiac function was preserved in these rats.

Conclusions

Application of a bioengineered 3DFC augments native angiogenesis through delivery of angiogenic cytokines to ischemic myocardium. This yields improved microvascular perfusion, limits infarct progression and adverse remodeling, and improves ventricular function.

CTSNet classification: 30, 31.2, 31.5, 38.2

Abbreviations and Acronyms: α-SMA, alpha smooth muscle actin, 3DFC, 3-dimensional human dermal fibroblast culture, dP/dt max, maximum rate of pressure rise, EDV, end-diastolic volume, ESV, end-systolic volume, HFSP, human fibroblast surface protein, HGF, hepatocyte growth factor, IU, intensity units, LAD, left anterior descending coronary artery, LV, left ventricular, LVID, left ventricular internal diameter, LVIDd, left ventricular end-diastolic diameter, LVIDs, left ventricular end-systolic diameter, PECAM, platelet endothelial cell adhesion molecule, SCID, severe combined immunodeficient, VEGF, vascular endothelial growth factor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported in part by NIH R01 HL072812 (to Y.J.W.), NIH/TSFRE K08 HL072812 (to Y.J.W.), an ISHLT Research Fellowship Grant (to J.R.F. III), and NIH HL07843 (to J.R.F.).

 Disclosures: None.

PII: S0022-5223(10)00024-3

doi:10.1016/j.jtcvs.2009.12.037

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 3 , Pages 667-676, September 2010